[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Becton Dickinson and Company (BDX)

Becton Dickinson and Company (BDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is ResMed Stock Underperforming the Dow?

With a market cap of $28.1 billion, San Diego, California-based ResMed Inc. (RMD) develops and markets medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders worldwide. The company operates through two segments: Sleep and Breathing Health, and Residential Care Software, offering solutions ranging from sleep diagnostics and therapy devices to comprehensive healthcare software platforms. 

Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and ResMed fits this criterion perfectly. Its innovations include portable diagnostic tools, cloud-based monitoring systems, and enterprise software solutions supporting sleep clinics, home medical equipment providers, and senior care organizations.

Fundamentals

See More
  • Market Capitalization, $K 40,294,972
  • Shares Outstanding, K 275,540
  • Annual Sales, $ 21,840 M
  • Annual Income, $ 1,678 M
  • EBIT $ 2,221 M
  • EBITDA $ 4,683 M
  • 60-Month Beta 0.22
  • Price/Sales 1.86
  • Price/Cash Flow 6.40
  • Price/Book 1.71

Options Overview Details

View History
  • Implied Volatility 26.50% (-1.85%)
  • Historical Volatility 30.92%
  • IV Percentile 33%
  • IV Rank 40.79%
  • IV High 38.88% on 02/06/26
  • IV Low 17.97% on 08/15/25
  • Expected Move (DTE 5) 4.82 (3.30%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 410
  • Volume Avg (30-Day) 1,226
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 20,450
  • Open Int (30-Day) 17,681
  • Expected Range 141.42 to 151.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.12
  • Number of Estimates 7
  • High Estimate $3.19
  • Low Estimate $3.06
  • Prior Year $3.68
  • Growth Rate Est. (year over year) -15.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.82 +3.12%
on 05/19/26
153.24 -4.57%
on 06/05/26
-1.27 (-0.86%)
since 05/12/26
3-Month
141.82 +3.12%
on 05/19/26
163.44 -10.52%
on 03/17/26
-13.39 (-8.39%)
since 03/12/26
52-Week
127.59 +14.62%
on 11/06/25
187.35 -21.94%
on 02/24/26
+9.09 (+6.62%)
since 06/12/25

Most Recent Stories

More News
Is ResMed Stock Underperforming the Dow?

While ResMed has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

BDX : 146.24 (-0.75%)
RMD : 194.78 (+1.24%)
$DOWI : 51,202.26 (+0.70%)
Becton, Dickinson and Company Stock: Is BDX Underperforming the Healthcare Sector?

Although Becton, Dickinson and Company has underperformed its sector peers recently, analysts remain moderately optimistic about the stock’s prospects.

XLV : 153.81 (-0.18%)
BDX : 146.24 (-0.75%)
ISRG : 411.06 (-0.45%)
Is Stryker Stock Underperforming the S&P 500?

Despite Stryker’s underperformance relative to the S&P 500 Index over the past year, Wall Street analysts remain highly bullish about the stock’s prospects.

SYK : 312.20 (+2.15%)
$SPX : 7,431.46 (+0.50%)
BDX : 146.24 (-0.75%)
Intuitive Surgical Stock: Is ISRG Underperforming the Healthcare Sector?

Despite recent underperformance relative to the healthcare sector, analysts remain fairly bullish on Intuitive Surgical's long-term fundamentals and growth potential.

XLV : 153.81 (-0.18%)
BDX : 146.24 (-0.75%)
ISRG : 411.06 (-0.45%)
3 Dividend Kings That Earn Their Crown Every Quarter

These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

JNJ : 240.87 (+1.07%)
BDX : 146.24 (-0.75%)
KVUE : 18.14 (+0.39%)
PEP : 144.27 (+0.38%)
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System

New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures.

BDX : 146.24 (-0.75%)
Is Wall Street Bullish or Bearish on Becton, Dickinson and Company Stock?

After the stock’s decline this year, do Wall Street analysts see a recovery in Becton, Dickinson and Company?

XLV : 153.81 (-0.18%)
$SPX : 7,431.46 (+0.50%)
BDX : 146.24 (-0.75%)
WAT : 355.53 (-1.17%)
Peter Menziuso Named EVP and President, BD Interventional

FRANKLIN LAKES, N.J. , May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named...

BDX : 146.24 (-0.75%)
Becton, Dickinson and Company Q2 Earnings Call Highlights

Becton, Dickinson and Company (NYSE:BDX) reported fiscal second-quarter revenue and adjusted earnings ahead of its internal expectations, while management raised its full-year adjusted earnings outlook...

BDX : 146.24 (-0.75%)
BD’s (NYSE:BDX) Q1 CY2026 Sales Beat Estimates

BD’s (NYSE:BDX) Q1 CY2026 Sales Beat Estimates

BDX : 146.24 (-0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational...

See More

Key Turning Points

3rd Resistance Point 153.29
2nd Resistance Point 151.15
1st Resistance Point 148.69
Last Price 146.24
1st Support Level 144.09
2nd Support Level 141.95
3rd Support Level 139.49

See More

52-Week High 187.35
Fibonacci 61.8% 164.52
Fibonacci 50% 157.47
Fibonacci 38.2% 150.42
Last Price 146.24
52-Week Low 127.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.